Allergen Research Corporation announced the appointments of Mary Rozenman, PhD, as Senior Vice President of Corporate and Commercial Development, and Mike Holfinger, PhD, as Vice President of Manufacturing. Dr. Rozenman and Dr. Holfinger fill key functions as ARC prepares for its upcoming Phase 3 clinical trial of the company's lead product, AR 101, a standardized pharmaceutical-grade peanut protein formulation for treating peanut allergy via characterized oral desensitization immunotherapy. Dr. Rozenman joins ARC from Longitude Capital, where she was a Vice President focused on biotechnology investments and was an observer on ARC's Board of Directors.

Dr. Holfinger joins ARC from Alexza Pharmaceuticals, where he was Vice President, Manufacturing and Global Supply Chain Management.